Processa Pharmaceuticals Inc [PCSA] stock is trading at $0.28, down -14.09%%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PCSA shares have gain 6.38% over the last week, with a monthly amount glided 14.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Processa Pharmaceuticals Inc [NASDAQ: PCSA] stock has seen the most recent analyst activity on April 25, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $8.
Processa Pharmaceuticals Inc [PCSA] stock has fluctuated between $0.15 and $3.10 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Processa Pharmaceuticals Inc [NASDAQ: PCSA] shares were valued at $0.28 at the most recent close of the market. An investor can expect a potential return of 3114.29% based on the average PCSA price forecast.
Analyzing the PCSA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.49, Equity is -3.2 and Total Capital is -3.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2501 points at the first support level, and at 0.2253 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3047, and for the 2nd resistance point, it is at 0.3345.
Ratios To Look Out For
For context, Processa Pharmaceuticals Inc’s Current Ratio is 2.93. As well, the Quick Ratio is 2.93, while the Cash Ratio is 2.26.
Transactions by insiders
Recent insider trading involved Yorke Justin W, Director, that happened on Jan 27 ’25 when 12400.0 shares were purchased. Chief Executive Officer, Ng George K completed a deal on Jan 27 ’25 to buy 87200.0 shares. Meanwhile, Pres. Research & Development Young David bought 0.12 million shares on Jan 27 ’25.
